BNT162b2 mRNA 疫苗在人类免疫缺陷病毒（HIV）感染者中引发强烈的体液和细胞免疫应答。
The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV).
机构信息
Department of Medicine, Johns Hopkins Medicine, Baltimore, Maryland, USA.
Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, Maryland, USA.
出版信息
Clin Infect Dis. 2022 Apr 9;74(7):1268-1270. doi: 10.1093/cid/ciab648.
Previous studies have shown that certain vaccines induce suboptimal responses in people living with human immunodeficiency virus (HIV, PLWH). However, responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have not been fully characterized in these patients. Here we show that the BNT162b2 vaccine induces robust immune responses comparable to responses in healthy donors.
先前的研究表明，某些疫苗会导致人类免疫缺陷病毒（HIV，PLWH）感染者产生不理想的反应。然而，这些患者对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗的反应尚未得到充分描述。在这里，我们表明 BNT162b2 疫苗可诱导出与健康供体相当的强大免疫反应。
Zotero 插件